Trevi Therapeutics (TRVI)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.30 (+11.54%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Trevi Therapeutics (TRVI)
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Key Insights

Critical company metrics and information
  • Share Price

    $2.76
  • Market Cap

    $212.15 Million
  • Total Outstanding Shares

    76.87 Million Shares
  • Total Employees

    27
  • Dividend

    No dividend
  • IPO Date

    May 3, 2019
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.trevitherapeutics.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow, Continuing$-9.91 Million
Net Cash Flow From Operating Activities$-35.06 Million
Net Cash Flow$-9.91 Million
Net Cash Flow From Investing Activities, Continuing$15.19 Million
Net Cash Flow From Operating Activities, Continuing$-35.06 Million
Net Cash Flow From Financing Activities, Continuing$9.96 Million
Net Cash Flow From Investing Activities$15.19 Million
Net Cash Flow From Financing Activities$9.96 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income Tax Expense/Benefit$28000.00
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Diluted Earnings Per Share$0.44
Revenues$0.00
Preferred Stock Dividends And Other Adjustments$0.00
Nonoperating Income/Loss$3.87 Million
Research and Development$36.57 Million
Basic Earnings Per Share$0.44
Diluted Average Shares$100.77 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Operating Expenses$48.21 Million
Income/Loss From Continuing Operations Before Tax$-44.34 Million
Operating Income/Loss$-48.21 Million
Basic Average Shares$100.77 Million
Net Income/Loss Attributable To Parent$-44.32 Million
Other Operating Expenses$11.65 Million
Net Income/Loss Available To Common Stockholders, Basic$-44.32 Million
Net Income/Loss$-44.32 Million
Income/Loss From Continuing Operations After Tax$-44.32 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Noncurrent Liabilities$816000.00
Other Current Assets$66.16 Million
Liabilities And Equity$68.91 Million
Equity Attributable To Noncontrolling Interest$0.00
Prepaid Expenses$1.18 Million
Current Liabilities$9.12 Million
Assets$68.91 Million
Equity$58.97 Million
Liabilities$9.94 Million
Equity Attributable To Parent$58.97 Million
Other Non-current Assets$1.40 Million
Other Current Liabilities$7.51 Million
Accounts Payable$1.61 Million
Noncurrent Assets$1.57 Million
Fixed Assets$174000.00
Current Assets$67.34 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.